How bimodal neuromodulation can soothe tinnitus symptoms: The impact of the TENT-A2 clinical trial results
Thursday, July 14
18:00 BST, 19:00 CEST, 13:00 EST
The results of Neuromod’s TENT-A2 clinical trial were recently published in the highly regarded scientific journal, Nature – Scientific Reports. This second large-scale trial follows on from the previous TENT-A1 clinical trial, and shows greater reduction in tinnitus symptom severity using bimodal neuromodulation device, Lenire®.
Join Dr Ross O’Neill and Prof. Hubert Lim for a webinar to discuss:
- How bimodal neuromodulation can soothe tinnitus symptoms;
- The background to the TENT-A2 clinical trial
- Why a second clinical trial was carried out
- The trial design and the different results per ARM
- What TENT-A2’s results mean for tinnitus patients and the future of Lenire.
- Interactive Q&A
The session will last about 1 hour with time for your questions.
Can’t make it on the day?
No problem. Register your interest and we will email you a recording of the webinar afterwards.
Registration has now closed
You can watch a recording of the webinar below
Meet the speakers
Dr Ross O’Neill, PhD MBA
Founder & CEO
Ross is a biomedical engineer with a personal passion for developing neuromodulation therapies for hearing and auditory system disorders. He founded Neuromod in 2010 to develop non-invasive neuromodulation treatments for chronic neurological disorders.
Prof. Hubert Lim, PhD
Chief Scientific Officer
Hubert is the Chief Scientific Officer of Neuromod Devices and Professor in the Department of Biomedical Engineering and Otolaryngology at the University of Minnesota. He is one of the authors of the TENT-A2 paper.